Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Buy” by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned a consensus rating of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.6364.

Several equities analysts have commented on TSHA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Canaccord Genuity Group raised their price target on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Needham & Company LLC raised their price target on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the second quarter worth about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies during the third quarter worth about $40,000. Tower Research Capital LLC TRC grew its position in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after buying an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after buying an additional 4,607 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $5.55 on Thursday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 1 year low of $2.25 and a 1 year high of $7.30. The business has a fifty day simple moving average of $5.59 and a 200 day simple moving average of $5.11. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -14.61 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, sell-side analysts predict that Taysha Gene Therapies will post -0.47 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.